Related Experiment Video
Updated: Aug 14, 2026
07:07
Analysis of Learning and Memory Ability in an Alzheimer's Disease Mouse Model using the Morris Water Maze
Published on: October 29, 2019
Conquering Alzheimer's Disease by Self Treatment
Patrick L McGeer1, Edith McGeer1
1Aurin Biotech Inc., Vancouver, BC, Canada.
Journal of Alzheimer'S Disease : JAD
|March 23, 2018
Summary
Early detection and prevention strategies can conquer Alzheimer's disease (AD). Identifying individuals at risk through biomarkers allows for timely interventions, preventing cognitive decline before symptoms appear.
Area of Science:
- Neuroscience
- Biomarkers
- Preventive Medicine
Background:
- Alzheimer's disease (AD) pathology begins at least 10 years before clinical symptoms manifest.
- This preclinical window offers a significant opportunity for intervention and prevention.
- Current diagnostic methods can identify individuals at risk.
Purpose of the Study:
- To outline a strategy for conquering Alzheimer's disease.
- To identify individuals at risk before the onset of clinical signs.
- To implement preventive measures to halt disease progression.
Main Methods:
- Utilizing biotechnology markers to detect early AD.
- Employing positron emission tomography (PET) for senile plaque detection.
- Analyzing blood or saliva for elevated amyloid-beta (Aβ42) fragments.
- Assessing cerebrospinal fluid (CSF) for decreased Aβ42 levels.
- Saliva analysis is highlighted as the simplest and least invasive method.
Main Results:
- Biomarkers indicate AD onset a decade prior to cognitive deficits.
- Early identification of at-risk individuals is feasible.
- Non-invasive methods like saliva analysis can detect at-risk individuals.
Conclusions:
- Alzheimer's disease can be conquered by identifying at-risk individuals early.
- Preventive measures include lifestyle changes and targeted treatments.
- Intervention during the preclinical phase is key to preventing cognitive decline.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...